Rilzabrutinib Approved for Tough Adult ITP Cases
Rilzabrutinib has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) as of 29 May 2026. This treatment is specifically indicated for adults with immune thrombocytopenia (ITP) when other therapies have failed...
Read moreDetails




























































